172 related articles for article (PubMed ID: 37173935)
1. Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways.
Nakamura K; Asanuma K; Okamoto T; Iino T; Hagi T; Nakamura T; Sudo A
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173935
[TBL] [Abstract][Full Text] [Related]
2. Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells.
Asanuma K; Nakamura T; Nakamura K; Hagi T; Okamoto T; Kita K; Matsuyama Y; Yoshida K; Asanuma Y; Sudo A
Anticancer Res; 2022 Sep; 42(9):4319-4328. PubMed ID: 36039444
[TBL] [Abstract][Full Text] [Related]
3. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
4. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
5. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
6. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779
[TBL] [Abstract][Full Text] [Related]
7. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
8. A Novel Peptide from Vespa ducalis Induces Apoptosis in Osteosarcoma Cells by Activating the p38 MAPK and JNK Signaling Pathways.
Wu R; Li D; Tang Q; Wang W; Xie G; Dou P
Biol Pharm Bull; 2018; 41(4):458-464. PubMed ID: 29607921
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
[TBL] [Abstract][Full Text] [Related]
11. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
12. Silibinin activated p53 and induced autophagic death in human fibrosarcoma HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways.
Duan WJ; Li QS; Xia MY; Tashiro S; Onodera S; Ikejima T
Biol Pharm Bull; 2011; 34(1):47-53. PubMed ID: 21212516
[TBL] [Abstract][Full Text] [Related]
13. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
14. Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells.
Chen HJ; Lin CM; Lee CY; Shih NC; Peng SF; Tsuzuki M; Amagaya S; Huang WW; Yang JS
Oncol Rep; 2013 Aug; 30(2):925-32. PubMed ID: 23708932
[TBL] [Abstract][Full Text] [Related]
15. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
16. [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells].
Fu BB; Fan Y; Hao LC; Liao AJ; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):671-5. PubMed ID: 21729547
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib.
Francisco V; Ruiz-Fernández C; González-Rodríguez M; Cordero-Barreal A; Pino J; Viñuela JE; Lago F; Conde J; Gómez R; Carvalho GR; Costa Pereira TM; Campos-Toimil M; Gualillo O
J Ethnopharmacol; 2021 May; 272():113932. PubMed ID: 33609728
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
19. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Tsuchiya H
BMC Cancer; 2019 Jul; 19(1):689. PubMed ID: 31307409
[TBL] [Abstract][Full Text] [Related]
20. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
